Literature DB >> 6801136

Ipr gene control of the anti-DNA antibody response.

D S Pisetsky, S A Caster, J B Roths, E D Murphy.   

Abstract

The influence of the Ipr gene on the anti-DNA antibody response was investigated in MRL and B6 Ipr/Ipr inbred mice, MRL +/+ mice less than a yr of age produced low levels of anti-DNA antibody, whereas older animals of this strain demonstrated levels in some instances comparable to those of the more severely affected MRL Ipr/Ipr mice. This result indicates a tendency to autoreactivity in MRL mice independent of the Ipr gene. To determine whether other mice bearing the Ipr gene would also express autoantibodies, the anti-DNA antibody responses of B6 Ipr/Ipr mice were studied. This strain was development by matings to transfer the Ipr gene into another inbred background and allow evaluation of the action independent of other disturbances of the MRL mice. Mice of this strain produced antibodies to DNA, with female animals displaying significantly higher levels than males. This result demonstrates that the Ipr gene can stimulate autoantibody production in mice other than the MRL strain and does not require abnormalities unique to this background to potentiate autoreactivity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801136

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  The regulation and activation potential of autoreactive B cells.

Authors:  Michele L Fields; Su-Jean Seo; Simone A Nish; Jeff H Tsai; Andrew J Caton; Jan Erikson
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Administration of activated lymphocyte-derived DNA accelerates and aggravates lupus nephritis in B6/lpr mice: a new approach to modify a lupus murine model.

Authors:  Y Zhu; Y Yue; S Xiong
Journal:  Clin Exp Immunol       Date:  2018-07-23       Impact factor: 4.330

3.  Anti-IgM treatment of C57BL/6-1pr/1pr mice: depletion of B cells reduces 1pr gene-induced lymphoproliferation and mononuclear cell vasculitis.

Authors:  A Cerny; M Kimoto; A W Hügin; R Merino; S Izui
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

4.  Lymphoid cell transfers between adult C57BL/6 mice differing at the lpr and/or nu locus. Humoral immunity phenotype of the chimeras.

Authors:  B Jachez; E Montecino-Rodriguez; F Pflumio; P Fonteneau; F Loor
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

Review 5.  Regulation of autoreactive anti-IgG (rheumatoid factor) B cells in normal and autoimmune mice.

Authors:  H Wang; M J Schlomchik
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

6.  Pin1-Targeted Therapy for Systemic Lupus Erythematosus.

Authors:  Shuo Wei; Nobuya Yoshida; Greg Finn; Shingo Kozono; Morris Nechama; Vasileios C Kyttaris; Xiao Zhen Zhou; George C Tsokos; Kun Ping Lu
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

Review 7.  Are autoantibodies the targets of B-cell-directed therapy?

Authors:  David S Pisetsky; Amrie C Grammer; Tony C Ning; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2011-08-02       Impact factor: 20.543

8.  Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice.

Authors:  Stephan Wueest; Reto A Rapold; Desiree M Schumann; Julia M Rytka; Anita Schildknecht; Ori Nov; Alexander V Chervonsky; Assaf Rudich; Eugen J Schoenle; Marc Y Donath; Daniel Konrad
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

9.  Defective LN cell proliferative response to Sm antigen in mice bearing the lpr gene.

Authors:  H Dang; M Fischbach; V Fey; N Talal
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

10.  Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis.

Authors:  Chuancang Jiang; Ming Lang Zhao; Marilyn Diaz
Journal:  Immunology       Date:  2008-06-20       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.